In partial agreement with our study, an earlier study among 179 Chinese NAFLD patients with and without diabetes (68 NASH cases and 111 non-NASH cases) reported that the serum levels of several biomarkers, including FGF-21, were significantly higher in NAFLD patients compared with healthy controls. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.